A Phase 1 trial involving octreotide-related compound Lutetium Lu 177 edotreotide was updated on September 17, 2026. The study, registered as NCT06441331, is titled "Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors." Its current status is listed as recruiting. The trial is designed to determine dosing and evaluate pharmacokinetics and safety of the therapy in pediatric participants with SSTR-positive tumors. This is a Phase 1 study, meaning it is an early-stage trial focused on dose-finding and initial safety assessment rather than efficacy outcomes. No results have been posted as part of this update. The listing does not include information on enrollment numbers, specific tumor types beyond SSTR-positive classification, or expected completion dates. Octreotide itself remains an approved compound, while this specific trial concerns the radiolabeled derivative Lutetium Lu 177 edotreotide. Readers interested in general background on octreotide can consult the compound overview for additional context on its approved uses and mechanism.
Phase 1 Trial of Lutetium Lu 177 Edotreotide in Pediatric SSTR Tumors Recruiting
See the full octreotide overview
Source: https://clinicaltrials.gov/study/NCT06441331